公开资料显示，山东金城医药集团股份有限公司成立于2004年，总部位于山东省淄博市，公司主要从事医药中间体、原料药、药物制剂、大健康产品、合成生物学产品的研发、生产与销售，以及医药中间体、原料药CMO/CDMO服务，是全球知名的头孢侧链中间体、生物发酵原料药谷胱甘肽、腺苷蛋氨酸产研基地，国内知名抗感染、妇科制剂生产商，拥有国内较丰富的头孢抗菌素及妇科全生命周期系列产品。① Tonight, Jincheng Pharmaceutical announced that the actual controller and chairman, Zhao Yeqing, was investigated by the Securities Regulatory Commission for suspected illegal acts of manipulating the securities market. ② Zhao Yeqing has been the chairman of Jincheng Pharmaceutical for 13 years. Her last appearance was at the 3rd China Pharmaceutical and Chemical Industry Conference two days ago. ③ 2024Q1, Jincheng Pharmaceutical has shown a positive trend of reversing last year's poor performance.
Financial Services Association, August 16 (Reporter Lu Afeng) On the evening of the 16th, Jincheng Pharmaceutical (300233.SZ), the first brother of cephalosporin pharmaceutical intermediates, suddenly announced that the actual controller, Zhao Yeqing, was investigated by the Securities Regulatory Commission on suspicion of manipulating the securities market in violation of laws and regulations.
Jincheng Pharmaceutical stressed in the announcement that the investigation was an investigation into his personal conduct and had nothing to do with the company's overall operations. The company's current production and operation situation is normal and has not been affected by this incident. As to whether Zhao Yeqing is suspected of manipulating the shares of its listed company or other listed companies, Jincheng Pharmaceutical did not disclose it.
According to public information, Shandong Jincheng Pharmaceutical Group Co., Ltd. was founded in 2004 and is headquartered in Zibo City, Shandong Province. The company is mainly engaged in R&D, production and sales of pharmaceutical intermediates, APIs, health products, synthetic biological products, and CMO/CDMO services for pharmaceutical intermediates and APIs. It is a world-renowned research base for cephalosporin side chain intermediates, biofermentation APIs glutathione, and adenosylmethionine. It is a well-known domestic manufacturer of anti-infective and gynecological preparations, and has a full range of cephalosporin and gynecological products.
Zhao Yeqing has been in the position of chairman of Jincheng Pharmaceutical for 13 years.
According to Tianyan Research, Zhao Yeqing worked at the Zibo Administration for Industry and Commerce from 1998 to 2000; since July 2004, he has served as Assistant General Manager, Executive Deputy General Manager, and Director of Shandong Jincheng Pharmaceutical & Chemical Co., Ltd. He is currently the Chairman of Shandong Jincheng Pharmaceutical Co., Ltd., Director of Jincheng Industrial, Executive Director of Shanghai Jincheng, and Chairman of Jincheng Jinsu.
Zhao Yeqing at the 3rd China Pharmaceutical and Chemical Industry Conference
On August 8, a conference celebrating the 20th anniversary of the establishment of Jincheng Pharmaceutical Group and its high-quality development was held at the Zibo Convention and Exhibition Center. Zhao Yeqing explained the future “12345” development layout of Jincheng Pharmaceutical in the five major fields of “pharmaceutical chemicals, synthetic biology, women's health technology, high-end anti-infection, and novel tobacco,” and signed a comprehensive strategic cooperation agreement with Jinan University on behalf of Jincheng Pharmaceutical.
A Finance Association reporter found that Jincheng Pharmaceutical still faced weak revenue growth and declining net profit last year, but successfully reversed the decline in 2024Q1.
In 2023, Jincheng Pharmaceutical's annual revenue was 3.538 billion yuan, which is basically the same as the previous year, achieving net profit of 0.175 billion yuan, a year-on-year decrease of 36.09%. Jincheng Pharmaceutical believes that this performance is due to the fact that the company's CMO product HR2002 intermediates did not achieve sales revenue, and the prices of some products in the company's intermediates and APIs business declined.
2024Q1, Jincheng Pharmaceutical's revenue increased 12.32% year on year, net profit to mother increased 65.43% year on year, and net profit after deducting non-net profit increased 87.19% year on year. However, Jincheng Pharmaceutical did not attribute the increase in performance in the Q1 report.
Jincheng Pharmaceutical's latest stock price peak of 19.29 yuan/share this year was May 8, and the day before was when Jincheng Pharmaceutical distributed its 2023 equity. Since then, Jincheng Pharmaceutical's stock price has begun to fluctuate and fall. Today's closing day rose slightly by 0.77%, and the stock price was 14.38 yuan/share.
A Financial Services News reporter learned that since the beginning of this year, the upward trend in Jincheng Pharmaceutical's stock price may have something to do with it being a “synthetic biology concept stock.”
According to its recently disclosed investor exchange records, Jincheng Pharmaceutical has been exploring the field of synthetic biology for 15 years. Compared with the vast majority of synthetic biology companies on the market, the company also has a biosynthetic R&D platform and industrialization platform, has the entire industrial chain platform and advantages of high-value-added biosynthetic products from R&D to pilot testing to industrial implementation, and has formed supporting varieties. The company has marketed and is developing more than 20 types of synthetic biology, including lebaudioside M, bosene, glutathione, and adenosylmethionine.
It is worth mentioning that Jincheng Pharmaceutical is a “major collector”. By the end of last year, Jincheng Pharmaceutical had 13 standard drugs, including injectable ceftazidil, injectable cefazolin sodium, and injectable piperacillin sodium and tazobactam sodium. There are also 7 standard drugs participating in local collection.
